New hope in battle to find cystic fibrosis cure

  • Experts say combining three drugs has major positive impact on lung condition
  • Two agents helped slow down lung damage in 40% of cystic fibrosis patients
  • Adding third element produces similar benefits in up to 90 per cent of patients

Mail on Sunday Reporter

1

View
comments

Cystic fibrosis sufferers have been given hope by a radical new treatment that could save thousands of people from an early death.

Scientists have found that combining three drugs has a major positive impact on the lung condition.

Researchers had earlier achieved success in combining two agents, which helped slow down lung damage in 40 per cent of cystic fibrosis patients. 

Cystic fibrosis sufferers have been given hope by a radical new treatment that could save thousands of people from an early death (file photo)

Cystic fibrosis sufferers have been given hope by a radical new treatment that could save thousands of people from an early death (file photo)

Cystic fibrosis sufferers have been given hope by a radical new treatment that could save thousands of people from an early death (file photo)

Now they have shown that adding a third element produces similar benefits in up to 90 per cent of patients.

Drugs company Vertex, behind the research, said the results were ‘clear and compelling, indicating significant potential benefit’.

Cystic fibrosis affects 10,000 people in the UK – among them former PM Gordon Brown’s son, Fraser, 11. Sufferers’ lungs produce too much mucus, leading to scarring, and they often require transplants. 

Scientists have found that combining three drugs has a major positive impact on the lung condition (file photo)

Scientists have found that combining three drugs has a major positive impact on the lung condition (file photo)

Scientists have found that combining three drugs has a major positive impact on the lung condition (file photo)

Life expectancy has been growing, but half die before the age of 41.

Professor Jane Davies, honorary consultant in paediatric medicine at London’s Royal Brompton Hospital, said if the ‘very, very early’ results held up in further trials, and the method proved to be safe, the triple-therapies could be used in ‘between 70 and 90 per cent of patients globally’.

Beyond larger trials, the next hurdle is cost. One of the drugs, Orkambi, has a ‘list price’ of £104,000 per patient per year and is not yet available on the NHS.

Comments 1

Share what you think

The comments below have not been moderated.

The views expressed in the contents above are those of our users and do not necessarily reflect the views of MailOnline.

Close

Your comment will be posted to MailOnline as usual.

 

Close

Your comment will be posted to MailOnline as usual

We will automatically post your comment and a link to the news story to your Facebook timeline at the same time it is posted on MailOnline. To do this we will link your MailOnline account with your Facebook account. We’ll ask you to confirm this for your first post to Facebook.

You can choose on each post whether you would like it to be posted to Facebook. Your details from Facebook will be used to provide you with tailored content, marketing and ads in line with our Privacy Policy.